Ketones and the cardiovascular system.
Journal
Nature cardiovascular research
ISSN: 2731-0590
Titre abrégé: Nat Cardiovasc Res
Pays: England
ID NLM: 9918284280206676
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
14
10
2022
accepted:
28
02
2023
medline:
1
5
2023
pubmed:
1
5
2023
entrez:
28
8
2024
Statut:
ppublish
Résumé
Ketone bodies, the main one being β-hydroxybutyrate, have emerged as important regulators of the cardiovascular system. In healthy individuals, as well as in individuals with heart failure or post-myocardial infarction, ketones provide a supplemental energy source for both the heart and the vasculature. In the failing heart, this additional energy may contribute to improved cardiac performance, whereas increasing ketone oxidation in vascular smooth muscle and endothelial cells enhances cell proliferation and prevents blood vessel rarefication. Ketones also have important actions in signaling pathways, posttranslational modification pathways and gene transcription; many of which modify cell proliferation, inflammation, oxidative stress, endothelial function and cardiac remodeling. Attempts to therapeutically increase ketone delivery to the cardiovascular system are numerous and have shown mixed results in terms of effectiveness. Here we review the bioenergetic and signaling effects of ketones on the cardiovascular system, and we discuss how ketones can potentially be used to treat cardiovascular diseases.
Identifiants
pubmed: 39196044
doi: 10.1038/s44161-023-00259-1
pii: 10.1038/s44161-023-00259-1
doi:
Substances chimiques
Ketones
0
Ketone Bodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
425-437Subventions
Organisme : Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada)
ID : 1154302
Informations de copyright
© 2023. Springer Nature Limited.
Références
Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R. & Abel, E. D. Cardiac energy metabolism in heart failure. Circ. Res. 128, 1487–1513 (2021).
pubmed: 33983836
pmcid: 8136750
doi: 10.1161/CIRCRESAHA.121.318241
Weis, E. M. et al. Ketone body oxidation increases cardiac endothelial cell proliferation. EMBO Mol. Med. 14, e14753 (2022). This paper showed ketones have a key role in preventing endothelial cell rarefication in heart failure.
pubmed: 35179309
pmcid: 8988203
doi: 10.15252/emmm.202114753
Lopaschuk, G. D., Hess, D. A. & Verma, S. Ketones regulate endothelial homeostasis. Cell Metab. 34, 513–515 (2022).
pubmed: 35385704
doi: 10.1016/j.cmet.2022.03.008
Youm, Y. H. et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263–269 (2015).
pubmed: 25686106
pmcid: 4352123
doi: 10.1038/nm.3804
Aubert, G. et al. The failing heart relies on ketone bodies as a fuel. Circulation 133, 698–705 (2016). This paper identified that ketone oxidation is increased in the failing heart.
pubmed: 26819376
pmcid: 4766035
doi: 10.1161/CIRCULATIONAHA.115.017355
Horton, J. L. et al. The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight 4, e124079 (2019).
pubmed: 30668551
pmcid: 6478419
doi: 10.1172/jci.insight.124079
Bedi, K. C. Jr et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation. 133, 706–716 (2016). This paper showed that ketone oxidation is increased in the failing heart.
Voros, G. et al. Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling. Circ. Heart Fail. 11, e004953 (2018).
pubmed: 30562098
doi: 10.1161/CIRCHEARTFAILURE.118.004953
Ho, K. L. et al. Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency. Cardiovasc. Res. 115, 1606–1616 (2019).
pubmed: 30778524
pmcid: 6704391
doi: 10.1093/cvr/cvz045
Chace, K. V. & Odessey, R. The utilization by rabbit aorta of carbohydrates, fatty acids, ketone bodies, and amino acids as substrates for energy production. Circ. Res. 48, 850–858 (1981).
pubmed: 7226445
doi: 10.1161/01.RES.48.6.850
Shugar, R. C. et al. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol. Metab. 3, 754–769 (2014).
doi: 10.1016/j.molmet.2014.07.010
Wentz, A. E. et al. Adaptation of myocardial substrate metabolism to a ketogenic nutrient environment. J. Biol. Chem. 285, 24447–24456 (2010).
pubmed: 20529848
pmcid: 2915681
doi: 10.1074/jbc.M110.100651
Verma, S. et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC Basic Transl. Sci. 3, 575–587 (2018). This paper shows that SGLT2 inhibitors can increase ketone oxidation in the failing heart.
pubmed: 30456329
pmcid: 6234616
doi: 10.1016/j.jacbts.2018.07.006
Bae, H. R. et al. β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation. Oncotarget 7, 66444–66454 (2016).
pubmed: 27661104
pmcid: 5341812
doi: 10.18632/oncotarget.12119
Han, Y. M. et al. β-Hydroxybutyrate prevents vascular senescence through hnRNP A1-mediated upregulation of Oct4. Mol. Cell 71, 1064–1078 (2018).
pubmed: 30197300
pmcid: 6230553
doi: 10.1016/j.molcel.2018.07.036
Miyamoto, J. et al. Ketone body receptor GPR43 regulates lipid metabolism under ketogenic conditions. Proc. Natl Acad. Sci. USA 116, 23813–23821 (2019).
pubmed: 31685604
pmcid: 6876247
doi: 10.1073/pnas.1912573116
Xie, Z. et al. Metabolic regulation of gene expression by histone lysine β-hydroxybutyrylation. Mol. Cell 62, 194–206 (2016). This paper shows an important role of ketones in regulating β-hydroxybutrylatiin in the heart.
Ruan, H.-B. & Crawford, P. A. Ketone bodies as epigenetic modifiers. Curr. Opin. Clin. Nutr. Metab. Care 21, 260–266 (2018).
pubmed: 29697540
doi: 10.1097/MCO.0000000000000475
Li, B. et al. β-Hydroxybutyrate inhibits histone deacetylase 3 to promote claudin-5 generation and attenuate cardiac microvascular hyperpermeability in diabetes. Diabetologia 64, 226–239 (2021).
Robinson, A. M. & Williamson, D. H. Physiological roles of ketone bodies as substrates and signals in mammalian tissues. Physiol. Rev. 60, 143–187 (1980).
pubmed: 6986618
doi: 10.1152/physrev.1980.60.1.143
Newman, J. C. & Verdin, E. Ketone bodies as signaling metabolites. Trends Endocrinol. Metab. 25, 42–52 (2014).
pubmed: 24140022
doi: 10.1016/j.tem.2013.09.002
Mierziak, J., Burgberger, M. & Wojtasik, W. 3-Hydroxybutyrate as a metabolite and a signal molecule regulating processes of living organisms. Biomolecules. 11, 402 (2021).
pubmed: 33803253
pmcid: 8000602
doi: 10.3390/biom11030402
Koronowski, K. B. et al. Ketogenesis impact on liver metabolism revealed by proteomics of lysine β-hydroxybutyrylation. Cell Rep. 36, 109487 (2021).
pubmed: 34348140
pmcid: 8372761
doi: 10.1016/j.celrep.2021.109487
Lopaschuk, G. D. & Verma, S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl. Sci. 5, 632–644 (2020).
pubmed: 32613148
pmcid: 7315190
doi: 10.1016/j.jacbts.2020.02.004
Nielsen, R. et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation 139, 2129–2141 (2019). This paper shows that administration of ketones to patients with heart failure can acutely improve heart function.
Byrne, N. J. et al. Chronically elevating circulating ketones can reduce cardiac inflammation and blunt the development of heart failure. Circ. Heart Fail. 13, e006573 (2020).
pubmed: 32493060
doi: 10.1161/CIRCHEARTFAILURE.119.006573
Puchalska, P. & Crawford, P. A. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 25, 262–284 (2017).
pubmed: 28178565
pmcid: 5313038
doi: 10.1016/j.cmet.2016.12.022
Kim, J. M. et al. Comparative proteomic analysis reveals the upregulation of ketogenesis in cardiomyocytes differentiated from induced pluripotent stem cells. Proteomics 19, e1800284 (2019).
pubmed: 30724459
doi: 10.1002/pmic.201800284
Song, J. P. et al. Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy. Sci. Transl. Med. 12, eaay8329 (2020).
pubmed: 32051229
doi: 10.1126/scitranslmed.aay8329
Cahill, G. F. Jr. Starvation in man. N. Eng. J. Med. 282, 668–675 (1970).
doi: 10.1056/NEJM197003192821209
Cahill, G. F. Jr & Veech, R. L. Ketoacids? Good medicine? Trans. Am. Clin. Climatol. Assoc. 114, 149–163 (2003).
pubmed: 12813917
pmcid: 2194504
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D., Jaswal, J. S. & Stanley, W. C. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 90, 207–258 (2010).
pubmed: 20086077
doi: 10.1152/physrev.00015.2009
Yan, J. et al. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 119, 2818–2828 (2009).
pubmed: 19451348
pmcid: 2765220
doi: 10.1161/CIRCULATIONAHA.108.832915
Nagao, M. et al. beta-Hydroxybutyrate elevation as a compensatory response against oxidative stress in cardiomyocytes. Biochem. Biophys. Res. Commun. 475, 322–328 (2016).
pubmed: 27216458
doi: 10.1016/j.bbrc.2016.05.097
Sato, K. et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 9, 651–658 (1995).
pubmed: 7768357
doi: 10.1096/fasebj.9.8.7768357
Ferrannini, E., Mark, M. & Mayoux, E. CV protection in the EMPA-REG OUTCOME trial: a ‘thrifty substrate’ hypothesis. Diabetes Care. 39, 1108–1114 (2016).
pubmed: 27289126
doi: 10.2337/dc16-0330
Mudaliar, S., Alloju, S. & Henry, R. R. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? a unifying hypothesis. Diabetes Care 39, 1115–1122 (2016).
pubmed: 27289124
doi: 10.2337/dc16-0542
Lopaschuk, G. D. & Verma, S. Empagliflozin’s fuel hypothesis: not so soon. Cell Metab. 24, 200–202 (2016).
pubmed: 27508868
doi: 10.1016/j.cmet.2016.07.018
De Bock, K. et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154, 651–663 (2013).
pubmed: 23911327
doi: 10.1016/j.cell.2013.06.037
García-Caballero, M. et al. Role and therapeutic potential of dietary ketone bodies in lymph vessel growth. Nat. Metab. 1, 666–675 (2019).
Shimazu, T. et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211–214 (2013).
pubmed: 23223453
doi: 10.1126/science.1227166
Butts, B., Gary, R. A., Dunbar, S. B. & Butler, J. The importance of NLRP3 inflammasome in heart failure. J. Card. Fail. 21, 586–593 (2015).
pubmed: 25982825
pmcid: 4516025
doi: 10.1016/j.cardfail.2015.04.014
Jahng, J. W., Song, E. & Sweeney, G. Crosstalk between the heart and peripheral organs in heart failure. Exp. Mol. Med. 48, e217 (2016).
pubmed: 26964833
pmcid: 4892881
doi: 10.1038/emm.2016.20
Bae, H. R. et al. beta-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation. Oncotarget 7, 66444–66454 (2016).
pubmed: 27661104
pmcid: 5341812
doi: 10.18632/oncotarget.12119
Srivastava, S. et al. Mitochondrial biogenesis and increased uncoupling protein 1 in brown adipose tissue of mice fed a ketone ester diet. FASEB J. 26, 2351–2362 (2012).
pubmed: 22362892
pmcid: 3360149
doi: 10.1096/fj.11-200410
Thai, P. N. et al. Mitochondrial quality control in aging and heart failure: influence of ketone bodies and mitofusin-stabilizing peptides. Front. Physiol. 10, 382 (2019).
pubmed: 31024341
pmcid: 6467974
doi: 10.3389/fphys.2019.00382
Thai, P. N. et al. Ketone ester D-β-Hydroxybutyrate-(R)-1,3 butanediol prevents decline in cardiac function in type 2 diabetic mice. J. Am. Heart Assoc. 10, e020729 (2021).
Vilà-Brau, A., De Sousa-Coelho, A. L., Mayordomo, C., Haro, D. & Marrero, P. F. Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line. J. Biol. Chem. 286, 20423–20430 (2011).
pubmed: 21502324
pmcid: 3121469
doi: 10.1074/jbc.M111.235044
Salomón, T. et al. Ketone body acetoacetate buffers methylglyoxal via a non-enzymatic conversion during diabetic and dietary ketosis. Cell Chem. Biol. 24, 935–943 (2017).
pubmed: 28820963
doi: 10.1016/j.chembiol.2017.07.012
Xia, S. et al. Prevention of dietary-fat-fueled ketogenesis attenuates BRAF V600E tumor growth. Cell Metab. 25, 358–373 (2017).
pubmed: 28089569
pmcid: 5299059
doi: 10.1016/j.cmet.2016.12.010
Taggart, A. K. et al. (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 280, 26649–26652 (2005).
pubmed: 15929991
doi: 10.1074/jbc.C500213200
Zhang, S. J. et al. Ketone body 3-hydroxybutyrate ameliorates atherosclerosis via receptor Gpr109a-mediated calcium influx. Adv. Sci. 8, 2003410 (2021).
doi: 10.1002/advs.202003410
Youm, Y. H. et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263–269 (2015). This paper shows that ketones can decrease inflammation by inhibiting the NLRP3 inflammasone.
pubmed: 25686106
pmcid: 4352123
doi: 10.1038/nm.3804
Shi, X. et al. NEFAs activate the oxidative stress-mediated NF-κB signaling pathway to induce inflammatory response in calf hepatocytes. J. Steroid Biochem. Mol. Biol. 145, 103–112 (2015).
pubmed: 25465477
doi: 10.1016/j.jsbmb.2014.10.014
Deng, Y. et al. Targeting mitochondria-inflammation circuit by β-hydroxybutyrate mitigates HFpEF. Circ. Res. 128, 232–245 (2021).
pubmed: 33176578
doi: 10.1161/CIRCRESAHA.120.317933
Soni, S. et al. Exogenous ketone ester administration attenuates systemic inflammation and reduces organ damage in a lipopolysaccharide model of sepsis. Biochim. Biophys. Acta Mol. Basis Dis. 1868, 166507 (2022).
pubmed: 35902007
doi: 10.1016/j.bbadis.2022.166507
Karagiannis, F. et al. Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19. Nature 609, 801–807 (2022).
pubmed: 35901960
pmcid: 9428867
doi: 10.1038/s41586-022-05128-8
Kim, S. R. et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 11, 2127 (2020).
pubmed: 32358544
pmcid: 7195385
doi: 10.1038/s41467-020-15983-6
Ye, Y., Bajaj, M., Yang, H. C., Perez-Polo, J. R. & Birnbaum, Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc. Drugs Ther. 31, 119–132 (2017).
pubmed: 28447181
doi: 10.1007/s10557-017-6725-2
Byrne, N. J. et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ. Heart. Fail. 13, e006277 (2020).
pubmed: 31957470
doi: 10.1161/CIRCHEARTFAILURE.119.006277
Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015). This study showed that SGLT2 inhibitors can lessen the severity of heart failure in individuals with diabetes.
Byrne, N. J. et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl. Sci. 2, 347–354 (2017).
pubmed: 30062155
pmcid: 6034464
doi: 10.1016/j.jacbts.2017.07.003
Philippaert, K. et al. Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 143, 2188–2204 (2021).
pubmed: 33832341
pmcid: 8154177
doi: 10.1161/CIRCULATIONAHA.121.053350
Dyck, J. R. B. et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J. Mol. Cell. Cardiol. 167, 17–31 (2022).
pubmed: 35331696
doi: 10.1016/j.yjmcc.2022.03.005
Van Lint, C., Emiliani, S. & Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245–253 (1996).
pubmed: 8723390
Kops, G. J. et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419, 316–321 (2002).
pubmed: 12239572
doi: 10.1038/nature01036
Ji, L. et al. Ketone body β-Hydroxybutyrate prevents myocardial oxidative stress in septic cardiomyopathy. Oxid. Med. Cell. Longev. 2022, 2513837 (2022).
pubmed: 35340211
pmcid: 8956399
doi: 10.1155/2022/2513837
Ling, X. B. et al. Mammalian metallothionein-2A and oxidative stress. Int. J. Mol. Sci. 17, 1483 (2016).
pubmed: 27608012
pmcid: 5037761
doi: 10.3390/ijms17091483
Oka, S. I. et al. β-Hydroxybutyrate, a ketone body, potentiates the antioxidant defense via thioredoxin 1 upregulation in cardiomyocytes. Antioxidants 10, 1153 (2021).
pubmed: 34356388
pmcid: 8301070
doi: 10.3390/antiox10071153
Zouhir, S. et al. The structure of the Slrp–Trx1 complex sheds light on the autoinhibition mechanism of the type III secretion system effectors of the NEL family. Biochem. J. 464, 135–144 (2014).
pubmed: 25184225
doi: 10.1042/BJ20140587
Li, B. et al. β-Hydroxybutyrate inhibits histone deacetylase 3 to promote claudin-5 generation and attenuate cardiac microvascular hyperpermeability in diabetes. Diabetologia. 64, 226–239 (2021).
pubmed: 33106900
doi: 10.1007/s00125-020-05305-2
Greene, C., Hanley, N. & Campbell, M. Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS. 16, 3 (2019).
pubmed: 30691500
pmcid: 6350359
doi: 10.1186/s12987-019-0123-z
Xie, Z. et al. Metabolic regulation of gene expression by histone lysine β-hydroxybutyrylation. Mol Cell. 62, 194–206 (2016).
pubmed: 27105115
pmcid: 5540445
doi: 10.1016/j.molcel.2016.03.036
Zhang, X. et al. Molecular basis for hierarchical histone de-β-hydroxybutyrylation by SIRT3. Cell Discov. 5, 35 (2019).
pubmed: 31636949
pmcid: 6796883
doi: 10.1038/s41421-019-0103-0
Sangalli, J. R. et al. Characterization of histone lysine β-hydroxybutyrylation in bovine tissues, cells, and cumulus–oocyte complexes. Mol. Reprod. Dev. 89, 375–398 (2022).
pubmed: 35802460
doi: 10.1002/mrd.23630
Liu, K. et al. p53 β-hydroxybutyrylation attenuates p53 activity. Cell Death Dis. 10, 243 (2019).
pubmed: 30858356
pmcid: 6411878
doi: 10.1038/s41419-019-1463-y
Hou, W. et al. Quantitative proteomics analysis expands the roles of lysine β-hydroxybutyrylation pathway in response to environmental β-hydroxybutyrate. Oxid. Med. Cell. Longev. 2022, 4592170 (2022).
pubmed: 35251473
pmcid: 8894020
doi: 10.1155/2022/4592170
Balasse, E. O. & Fery, F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab. Rev. 5, 247–270 (1989).
pubmed: 2656155
doi: 10.1002/dmr.5610050304
Owen, O. E. et al. Brain metabolism during fasting. J. Clin. Invest. 46, 1589–1595 (1967).
pubmed: 6061736
pmcid: 292907
doi: 10.1172/JCI105650
Uchihashi, M. et al. Cardiac-specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload-induced heart failure. Circ. Heart Fail. 10, e004417 (2017).
pubmed: 29242353
doi: 10.1161/CIRCHEARTFAILURE.117.004417
Ma, X. et al. β-Hydroxybutyrate exacerbates hypoxic injury by inhibiting HIF-1α-dependent glycolysis in cardiomyocytes—adding fuel to the fire? Cardiovasc. Drugs Ther. 36, 383–397 (2022).
pubmed: 34652582
doi: 10.1007/s10557-021-07267-y
Holmes, M. V. et al.; China Kadoorie Biobank Collaborative Group.Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J. Am. Coll. Cardiol. 71, 620–632 (2018).
pubmed: 29420958
pmcid: 5811927
doi: 10.1016/j.jacc.2017.12.006
Arima, Y. et al. Myocardial ischemia suppresses ketone body utilization. J. Am. Coll. Cardiol. 73, 246–247 (2019).
pubmed: 30408507
doi: 10.1016/j.jacc.2018.10.040
Takahara, S., Soni, S., Maayah, Z. H., Ferdaoussi, M. & Dyck, J. R. B. Ketone therapy for heart failure: current evidence for clinical use. Cardiovasc Res. 118, 77–987 (2022).
doi: 10.1093/cvr/cvab068
Karwi, Q. G., Biswas, D., Pulinilkunnil, T. & Lopaschuk, G. D. Myocardial ketones metabolism in heart failure. J. Card. Fail. 26, 998–1005 (2020).
Tona, F., Montisci, R., Iop, L. & Civieri, G. Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. Cardiovasc Med. 22, 97–104 (2021).
Won, Y. J., Lu, V. B., Puhl, H. L. & Ikeda, S. R. ß-hydroxybutyrate modulates B-type calcium channels in rat sympathetic neurons by acting as an agonist for G-protein-coupled receptor FFA3. J. Neurosci. 33, 19314–19325 (2013).
pubmed: 24305827
pmcid: 3850046
doi: 10.1523/JNEUROSCI.3102-13.2013
Selvaraj, S. et al. Acute echocardiographic effects of exogenous ketone administration in healthy participants. J. Am. Soc. Echocardiogr. 35, 305–331 (2022).
pubmed: 34798244
doi: 10.1016/j.echo.2021.10.017
Monzo, L. et al. Myocardial ketone body utilization in patients with heart failure: the impact of oral ketone ester. Metabolism. 115, 154452 (2021).
pubmed: 33248064
doi: 10.1016/j.metabol.2020.154452
Takahara, S. et al. Chronic exogenous ketone supplementation blunts the decline of cardiac function in the failing heart. ESC Heart Fail. 8, 5606–5612 (2021).
pubmed: 34617412
pmcid: 8712827
doi: 10.1002/ehf2.13634
Yurista, S. R. et al. Ketone ester treatment improves cardiac function and reduces pathologic remodeling in preclinical models of heart failure. Circ. Heart Fail. 14, e007684 (2021). This study showed that ketone esters may be used to treat heart failure.
Nakamura, M. et al. Dietary carbohydrates restriction inhibits the development of cardiac hypertrophy and heart failure. Cardiovasc. Res. 117, 2365–2376 (2021).
pubmed: 33070172
doi: 10.1093/cvr/cvaa298
McCommis, K. S. et al. Nutritional modulation of heart failure in mitochondrial pyruvate carrier-deficient mice. Nat Metab. 2, 1232–1247 (2020).
pubmed: 33106690
pmcid: 7957960
doi: 10.1038/s42255-020-00296-1
Guo, Y. et al. Alternate-day ketogenic diet feeding protects against heart failure through preservation of ketogenesis in the liver. Oxid. Med. Cell. Longev. 2022, 4253651 (2022).
pubmed: 35707271
pmcid: 9192193
doi: 10.1155/2022/4253651
Ho, K. L. et al. Ketones can become the major fuel source for the heart but do not increase cardiac efficiency. Cardiovasc. Res. 117, 1178–1187 (2021).
pubmed: 32402081
doi: 10.1093/cvr/cvaa143
Xu, S. et al. Ketogenic diets inhibit mitochondrial biogenesis and induce cardiac fibrosis. Signal Transduct. Target. Ther. 6, 54 (2021).
pubmed: 33558457
pmcid: 7870678
doi: 10.1038/s41392-020-00411-4
Balietti, M. et al. A ketogenic diet increases succinic dehydrogenase activity in aging cardiomyocytes. Ann. N. Y. Acad. Sci. 1171, 377–384 (2009).
pubmed: 19723079
doi: 10.1111/j.1749-6632.2009.04704.x
Pietschner, R. et al. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. Cardiovasc. Diabetol. 20, 219 (2021).
pubmed: 34753480
pmcid: 8579532
doi: 10.1186/s12933-021-01410-7
Anker, S. D. et al. EMPEROR-preserved trial investigators. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
pubmed: 34449189
doi: 10.1056/NEJMoa2107038
Solomon, S. D. et al.; DELIVER trial committees and investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089–1098 (2022). This study showed that SGLT2 inhibitors can be used to treat patients with HFpEF.
McMurray, J. J. V. et al.; DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).
pubmed: 31535829
doi: 10.1056/NEJMoa1911303
McCarthy, C. G. et al. Ketone body β-hydroxybutyrate is an autophagy-dependent vasodilator. JCI Insight. 6, e149037 (2021).
pubmed: 34499623
pmcid: 8564907
doi: 10.1172/jci.insight.149037
McCarthy, C. G., Chakraborty, S., Schreckenberger, Z., Wenceslau, C. F. & Joe, B. β-Hydroxybutyrate increases nitric oxide synthase activity in resistance arteries from Dahl salt-sensitive rats. FASEB J. 33, 829.1–829.1 (2019).
doi: 10.1096/fasebj.2019.33.1_supplement.829.1
Chakraborty, S. et al. Salt-responsive metabolite, β-hydroxybutyrate, attenuates hypertension. Cell Rep. 25, 677–689 (2018).
pubmed: 30332647
pmcid: 6542293
doi: 10.1016/j.celrep.2018.09.058
Neal, E. G. et al. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy. Epilepsia 50, 1109–1117 (2009).
pubmed: 19054400
doi: 10.1111/j.1528-1167.2008.01870.x
Okere, I. C. et al. Low carbohydrate/high-fat diet attenuates cardiac hypertrophy, remodeling, and altered gene expression in hypertension. Hypertension 48, 1116–1123 (2006).
pubmed: 17060511
doi: 10.1161/01.HYP.0000248430.26229.0f
Al-Zaid, N. S., Dashti, H. M., Mathew, T. C. & Juggi, J. S. Low-carbohydrate ketogenic diet enhances cardiac tolerance to global ischaemia. Acta Cardiol. 62, 381–389 (2007).
pubmed: 17824299
doi: 10.2143/AC.62.4.2022282
Sharma, N. et al. High-sugar diets increase cardiac dysfunction and mortality in hypertension compared to low-carbohydrate or high-starch diets. J. Hypertens. 26, 1402–1410 (2008).
pubmed: 18551017
pmcid: 3103886
doi: 10.1097/HJH.0b013e3283007dda
Guo, Y. et al. Ketogenic diet ameliorates cardiac dysfunction via balancing mitochondrial dynamics and inhibiting apoptosis in type 2 diabetic mice. Aging Dis. 11, 229–240 (2020).
pubmed: 32257538
pmcid: 7069456
doi: 10.14336/AD.2019.0510
Wang, P., Tate, J. M. & Lloyd, S. G. Low-carbohydrate diet decreases myocardial insulin signaling and increases susceptibility to myocardial ischemia. Life Sci. 83, 836–844 (2008).
pubmed: 18951908
pmcid: 2642968
doi: 10.1016/j.lfs.2008.09.024
Cicero, A. F. et al. Middle and long-term impact of a very low-carbohydrate ketogenic diet on cardiometabolic factors: a multi-center, cross-sectional, clinical study. High Blood Press. Cardiovasc. Prev. 22, 389–394 (2015).
pubmed: 25986079
pmcid: 4666896
doi: 10.1007/s40292-015-0096-1
Foster, G. D. et al. A randomized trial of a low-carbohydrate diet for obesity. N. Engl. J. Med. 348, 2082–2090 (2003).
pubmed: 12761365
doi: 10.1056/NEJMoa022207
Samaha, F. F. et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N. Engl. J. Med. 348, 2074–2081 (2003).
pubmed: 12761364
doi: 10.1056/NEJMoa022637
Churuangsuk, C., Lean, M. E. J. & Combet, E. Lower carbohydrate and higher fat intakes are associated with higher hemoglobin A1c: findings from the UK National Diet and Nutrition Survey 2008–2016. Eur. J. Nutr. 59, 2771–2782 (2020).
pubmed: 31686204
doi: 10.1007/s00394-019-02122-1
Mezhnina, V. et al. Circadian clock controls rhythms in ketogenesis by interfering with PPARα transcriptional network. Proc. Natl Acad. Sci. USA 119, e2205755119 (2022).
pubmed: 36161962
pmcid: 9546578
doi: 10.1073/pnas.2205755119
Vandenberghe, C. et al. Medium chain triglycerides modulate the ketogenic effect of a metabolic switch. Front. Nutr. 7, 3 (2020).
pubmed: 32083091
pmcid: 7005013
doi: 10.3389/fnut.2020.00003
Clarke, K. et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul. Toxicol. Pharmacol. 63, 401–408 (2012).
pubmed: 22561291
doi: 10.1016/j.yrtph.2012.04.008
Fischer, T. et al. Effect of a sodium and calcium DL-β-hydroxybutyrate salt in healthy adults. J. Nutr. Metab. 2018, 9812806 (2018).
pubmed: 29850235
pmcid: 5925188
doi: 10.1155/2018/9812806
Caminhotto, R. O., Komino, A. C. M., de Fatima Silva, F. & Andreotti, S. Sertie RAL, Boltes Reis G and Lima FB. Oral beta-hydroxybutyrate increases ketonemia, decreases visceral adipocyte volume and improves serum lipid profile in Wistar rats. Nutr. Metab. 14, 31 (2017).
doi: 10.1186/s12986-017-0184-4
St-Pierre, V. et al. Plasma ketone and medium chain fatty acid response in humans consuming different medium chain triglycerides during a metabolic study day. Front. Nutr. 6, 46 (2019).
pubmed: 31058159
pmcid: 6481320
doi: 10.3389/fnut.2019.00046
Fortier, M. et al. A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement. 15, 625–634 (2019).
pubmed: 31027873
doi: 10.1016/j.jalz.2018.12.017
Han, J., Hamilton, J. A., Kirkland, J. L., Corkey, B. E. & Guo, W. Medium-chain oil reduces fat mass and down-regulates expression of adipogenic genes in rats. Obes. Res. 11, 734–744 (2003).
pubmed: 12805394
doi: 10.1038/oby.2003.103
Stubbs, B. J., Cox, P. J., Kirk, T., Evans, R. D. & Clarke, K. Gastrointestinal effects of exogenous ketone drinks are infrequent, mild and vary according to ketone compound and dose. Int. J. Sport Nutr. Exerc. Metab. 29, 596–603 (2019).
pubmed: 31034254
doi: 10.1123/ijsnem.2019-0014
Neudorf, H. et al. Oral ketone supplementation acutely increases markers of NLRP3 inflammasome activation in human monocytes. Mol. Nutr. Food Res. 63, e1801171 (2019).
pubmed: 30912285
doi: 10.1002/mnfr.201801171
Cuenoud, B. et al. Metabolism of exogenous D-beta-hydroxybutyrate, an energy substrate avidly consumed by the heart and kidney. Front. Nutr. 7, 13 (2020).
pubmed: 32140471
pmcid: 7042179
doi: 10.3389/fnut.2020.00013
Selvaraj, S., Kelly, D. P. & Margulies, K. B. Implications of altered ketone metabolism and therapeutic ketosis in heart failure. Circulation. 141, 1800–1812 (2020).
pubmed: 32479196
pmcid: 7304522
doi: 10.1161/CIRCULATIONAHA.119.045033
Leckey, J. J., Ross, M. L., Quod, M., Hawley, J. A. & Burke, L. M. Ketone diester ingestion impairs time-trial performance in professional cyclists. Front. Physiol. 8, 806 (2017).
pubmed: 29109686
pmcid: 5660098
doi: 10.3389/fphys.2017.00806
Cox, P. J. et al. Nutritional ketosis alters fuel preference and thereby endurance performance in athletes. Cell Metab. 24, 256–268 (2016).
pubmed: 27475046
doi: 10.1016/j.cmet.2016.07.010
Shaw, D. M. et al. The effect of 1,3-butanediol on cycling time-trial performance. Int. J. Sport Nutr. Exerc. Metab. 29, 466–473 (2019).
pubmed: 30632425
doi: 10.1123/ijsnem.2018-0284
Scott, B. E. et al. The effect of 1,3-butanediol and carbohydrate supplementation on running performance. J. Sci. Med. Sport 22, 702–706 (2019).
pubmed: 30553764
doi: 10.1016/j.jsams.2018.11.027
Dong, T. A. et al. Intermittent fasting: a heart healthy dietary pattern? Am. J. Med. 133, 901–907 (2020).
pubmed: 32330491
pmcid: 7415631
doi: 10.1016/j.amjmed.2020.03.030
Khan, M. S. et al. Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. Eur. J. Heart Fail. 23, 1468–1476 (2021).
pubmed: 34173307
doi: 10.1002/ejhf.2278